Related Experiment Video
Updated: Sep 21, 2025

06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.5K
Abstract:
Genentech's TIGIT-targeted antibody tiragolumab missed its endpoints in two late-stage lung cancer trials, raising doubts about one of the most widely studied next-generation checkpoint targets in immuno-oncology. But numerical signs of benefit among certain patients with metastatic non-small cell lung cancer suggest that TIGIT blockade still has potential-if drug developers can successfully identify the best indications, drug combinations, or patient populations.

